PRagmatic Study Of Messaging to Providers of Patients With Heart Failure in Amsterdam UMC

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)2 sites in 1 country900 target enrollmentMay 21, 2024

ConditionsHeart Failure With Reduced Ejection Fraction

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Heart Failure With Reduced Ejection Fraction
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Enrollment: 900
Locations: 2
Primary Endpoint: Use of guideline-directed medical therapy (GDMT)
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a prospective cohort study, where the investigators aim to investigate the effect of implementation of an electronic nudge alerting clinicians to the prescription of the 4 key pharmacological classes for the treatment of patients with heart failure and reduced ejection fraction (HFrEF) at the outpatient clinic in the Netherlands.

Registry

clinicaltrials.gov

Start Date

May 21, 2024

End Date

December 2025

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Responsible Party

Principal Investigator

Prof. Dr. Folkert W. Asselbergs

Principal Investigator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Eligibility Criteria

Inclusion Criteria

•Age \> 18 years
•Treatment for HFrEF at the outpatient clinic cardiology.
•Documented reduced ejection fraction of \<40% based on cardiac ultrasound or cardiac magnetic resonance imaging.

Exclusion Criteria

•Opt-out for the use of routine clinical data for research purposes

Outcomes

Primary Outcomes

Use of guideline-directed medical therapy (GDMT)

Time Frame: 30 days (primary), 6 months (secondary)

Using all therapies according to ESC guidelines

Secondary Outcomes

Hospitalisation for Heart Failure(6 months, 1 year)
renal events (>30% serum creatinine increase, hospitalization for acute kidney injury, development of end-stage kidney disease)(30 days, 6 months, 1 year)
All-cause mortality(1 year)
other major cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke)(6 months, 1 year)